Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan 26;1(1):CD015308.
doi: 10.1002/14651858.CD015308.

Interleukin-1 blocking agents for treating COVID-19

Mauricia Davidson #  1   2   3 , Sonia Menon #  1 , Anna Chaimani  1   2 , Theodoros Evrenoglou  1   2 , Lina Ghosn  1   2   3 , Carolina Graña  1   2   3 , Nicholas Henschke  4 , Elise Cogo  5 , Gemma Villanueva  6 , Gabriel Ferrand  1   2   3 , Carolina Riveros  1   2   3 , Hillary Bonnet  1   2   3 , Philipp Kapp  1   2   3 , Conor Moran  7 , Declan Devane  8 , Joerg J Meerpohl  9   10 , Gabriel Rada  11   12 , Asbjørn Hróbjartsson  13   14 , Giacomo Grasselli  15 , David Tovey  1   2 , Philippe Ravaud  1   2   3 , Isabelle Boutron  1   2   3
Affiliations
Review

Interleukin-1 blocking agents for treating COVID-19

Mauricia Davidson et al. Cochrane Database Syst Rev. .

Abstract

Background: Interleukin-1 (IL-1) blocking agents have been used for treating severe coronavirus disease 2019 (COVID-19), on the premise that their immunomodulatory effect might be beneficial in people with COVID-19.

Objectives: To assess the effects of IL-1 blocking agents compared with standard care alone or with placebo on effectiveness and safety outcomes in people with COVID-19. We will update this assessment regularly.

Search methods: We searched the Cochrane COVID-19 Study Register and the COVID-19 L-OVE Platform (search date 5 November 2021). These sources are maintained through regular searches of MEDLINE, Embase, CENTRAL, trial registers and other sources. We also checked the World Health Organization International Clinical Trials Registry Platform, regulatory agency websites, Retraction Watch (search date 3 November 2021).

Selection criteria: We included randomised controlled trials (RCTs) evaluating IL-1 blocking agents compared with standard care alone or with placebo for people with COVID-19, regardless of disease severity.

Data collection and analysis: We followed Cochrane methodology. The protocol was amended to reduce the number of outcomes considered. Two researchers independently screened and extracted data and assessed the risk of bias with the Cochrane Risk of Bias 2 tool. We rated the certainty of evidence using the GRADE approach for the critical outcomes of clinical improvement (Day 28; ≥ D60); WHO Clinical Progression Score of level 7 or above (i.e. the proportion of participants with mechanical ventilation +/- additional organ support OR death) (D28; ≥ D60); all-cause mortality (D28; ≥ D60); incidence of any adverse events; and incidence of serious adverse events.

Main results: We identified four RCTs of anakinra (three published in peer-reviewed journals, one reported as a preprint) and two RCTs of canakinumab (published in peer-reviewed journals). All trials were multicentre (2 to 133 centres). Two trials stopped early (one due to futility and one as the trigger for inferiority was met). The median/mean age range varied from 58 to 68 years; the proportion of men varied from 58% to 77%. All participants were hospitalised; 67% to 100% were on oxygen at baseline but not intubated; between 0% and 33% were intubated at baseline. We identified a further 16 registered trials with no results available, of which 15 assessed anakinra (four completed, four terminated, five ongoing, three not recruiting) and one (completed) trial assessed canakinumab. Effectiveness of anakinra for people with COVID-19 Anakinra probably results in little or no increase in clinical improvement at D28 (risk ratio (RR) 1.08, 95% confidence interval (CI) 0.97 to 1.20; 3 RCTs, 837 participants; absolute effect: 59 more per 1000 (from 22 fewer to 147 more); moderate-certainty evidence. The evidence is uncertain about an effect of anakinra on 1) the proportion of participants with a WHO Clinical Progression Score of level 7 or above at D28 (RR 0.67, 95% CI 0.36 to 1.22; 2 RCTs, 722 participants; absolute effect: 55 fewer per 1000 (from 107 fewer to 37 more); low-certainty evidence) and ≥ D60 (RR 0.54, 95% CI 0.30 to 0.96; 1 RCT, 606 participants; absolute effect: 47 fewer per 1000 (from 72 fewer to 4 fewer) low-certainty evidence); and 2) all-cause mortality at D28 (RR 0.69, 95% CI 0.34 to 1.39; 2 RCTs, 722 participants; absolute effect: 32 fewer per 1000 (from 68 fewer to 40 more); low-certainty evidence). The evidence is very uncertain about an effect of anakinra on 1) the proportion of participants with clinical improvement at ≥ D60 (RR 0.93, 95% CI 0.78 to 1.12; 1 RCT, 115 participants; absolute effect: 59 fewer per 1000 (from 186 fewer to 102 more); very low-certainty evidence); and 2) all-cause mortality at ≥ D60 (RR 1.03, 95% CI 0.68 to 1.56; 4 RCTs, 1633 participants; absolute effect: 8 more per 1000 (from 84 fewer to 147 more); very low-certainty evidence). Safety of anakinra for people with COVID-19 Anakinra probably results in little or no increase in adverse events (RR 1.02, 95% CI 0.94 to 1.11; 2 RCTs, 722 participants; absolute effect: 14 more per 1000 (from 43 fewer to 78 more); moderate-certainty evidence). The evidence is uncertain regarding an effect of anakinra on serious adverse events (RR 0.95, 95% CI 0.58 to 1.56; 2 RCTs, 722 participants; absolute effect: 12 fewer per 1000 (from 104 fewer to 138 more); low-certainty evidence). Effectiveness of canakinumab for people with COVID-19 Canakinumab probably results in little or no increase in clinical improvement at D28 (RR 1.05, 95% CI 0.96 to 1.14; 2 RCTs, 499 participants; absolute effect: 42 more per 1000 (from 33 fewer to 116 more); moderate-certainty evidence). The evidence of an effect of canakinumab is uncertain on 1) the proportion of participants with a WHO Clinical Progression Score of level 7 or above at D28 (RR 0.72, 95% CI 0.44 to 1.20; 2 RCTs, 499 participants; absolute effect: 35 fewer per 1000 (from 69 fewer to 25 more); low-certainty evidence); and 2) all-cause mortality at D28 (RR:0.75; 95% CI 0.39 to 1.42); 2 RCTs, 499 participants; absolute effect: 20 fewer per 1000 (from 48 fewer to 33 more); low-certainty evidence). The evidence is very uncertain about an effect of canakinumab on all-cause mortality at ≥ D60 (RR 0.55, 95% CI 0.16 to 1.91; 1 RCT, 45 participants; absolute effect: 112 fewer per 1000 (from 210 fewer to 227 more); very low-certainty evidence). Safety of canakinumab for people with COVID-19 Canakinumab probably results in little or no increase in adverse events (RR 1.02; 95% CI 0.86 to 1.21; 1 RCT, 454 participants; absolute effect: 11 more per 1000 (from 74 fewer to 111 more); moderate-certainty evidence). The evidence of an effect of canakinumab on serious adverse events is uncertain (RR 0.80, 95% CI 0.57 to 1.13; 2 RCTs, 499 participants; absolute effect: 44 fewer per 1000 (from 94 fewer to 28 more); low-certainty evidence).

Authors' conclusions: Overall, we did not find evidence for an important beneficial effect of IL-1 blocking agents. The evidence is uncertain or very uncertain for several outcomes. Sixteen trials of anakinra and canakinumab with no results are currently registered, of which four are completed, and four terminated. The findings of this review are updated on the COVID-NMA platform (covid-nma.com).

Trial registration: ClinicalTrials.gov NCT04330638.

PubMed Disclaimer

Conflict of interest statement

Mauricia Davidson: none known.

Sonia Menon: works as systematic reviewer for p95 consultancy company.

Anna Chaimani: none known.

Theodoros Evrenoglou: none known.

Lina Ghosn: none known.

Carolina Graña: none known.

Nicholas Henschke: is employed by Cochrane Response, an evidence consultancy initiative from Cochrane. Cochrane Response was commissioned by the WHO to perform work on the living systematic review and living network meta‐analysis for COVID‐19 studies.

Elise Cogo: is employed by Cochrane Response, an evidence consultancy initiative from Cochrane. Cochrane Response was commissioned by the WHO to perform work on the living systematic review and living network meta‐analysis for COVID‐19 studies.

Gemma Villanueva: is employed by Cochrane Response, an evidence consultancy initiative from Cochrane. Cochrane Response was commissioned by the WHO to perform work on the living systematic review and living network meta‐analysis for COVID‐19 studies.

Gabriel Ferrand: none known.

Carolina Riveros: none known.

Philipp Kapp: none known.

Hillary Bonnet: none known.

Conor Moran: none known.

Declan Devane: works for Cochrane Ireland and Evidence Synthesis Ireland which are funded within the National University of Ireland Galway (Ireland) by the Health Research Board (HRB) and the Health and Social Care, Research and Development (HSC R&D) Division of the Public Health Agency in Northern Ireland.

Joerg J Meerpohl: reports funding from the Federal Ministry of Health and the Federal Ministry of Education and Research.

Gabriel Rada: none known.

Asbjørn Hróbjartsson: none known.

Giacomo Grasselli: receives personal fees for lectures from Getinge, Fisher&Paykel, Draeger Medical, Biotest, Thermofisher and MSD; support for travel‐meeting expenses from Biotest and Getinge (all outside the present work). GG also received an unrestricted research grant from Fisher&Paykel (unrelated to the present work).

David Tovey: has a part‐time paid consultancy with the Université de Paris.

Philippe Ravaud: is a minority shareholder of INATO. PR was the methodologist of the CORIMUNO‐19 platform which generated the Mariette CORIMUNO‐19 Collaborative 2021 trial. PR did not undertake any inclusion decisions/data extraction or risk of bias assessments for the Mariette CORIMUNO‐19 Collaborative 2021 trial.

Isabelle Boutron: is director of Cochrane France and co‐convenor of the Cochrane Bias methods group.

Figures

1
1
Flowchart of included randomised controlled trials (RCTs) of interleukin 1 (IL‐1) blocking agents (last search date 5 November 2021) COVID‐NMA is a living systematic review of all trials assessing treatment and preventive interventions for COVID‐19 (Boutron 2020b). This review is a subreview of COVID‐NMA. ICTRP: World Health Organization (WHO) International Clinical Trials Registry Platform
2
2
Analysis 1.1.1: Anakinra versus standard care/placebo: Clinical improvement D28
3
3
Analysis 1.1.2: Anakinra versus standard care/placebo: Clinical improvement D60 or above
4
4
Analysis 1.1.3: Anakinra versus standard care/placebo: WHO Clinical Progression Score of level 7 or above D28
5
5
Analysis 1.1.4: Anakinra versus standard care/placebo: WHO Clinical Progression Score of level 7 or above D60 or above
6
6
Analysis 1.1.5: Anakinra versus standard care/placebo: All‐cause mortality D28
7
7
Analysis 1.1.6: Anakinra versus placebo or standard care. Outcome: All‐cause mortality D60 or above
8
8
Analysis 1.1.7: Anakinra versus standard care/placebo: Adverse Events
9
9
Analysis 1.1.8: Anakinra versus standard care/placebo: Serious adverse events
10
10
Analysis 2.1.1: Canakinumab versus standard care/placebo: Clinical improvement D28
11
11
Analysis 2.1.2: Canakinumab versus standard care/placebo: WHO Clinical Progression Score of level 7 or above D28
12
12
Analysis 2.1.3: Canakinumab versus standard care/placebo: All‐cause mortality D28
13
13
Analysis 2.1.4: Canakinumab versus standard care/placebo: All‐cause mortality D60 or above
14
14
Analysis 2.1.5: Canakinumab versus standard care/placebo: Adverse events
15
15
Analysis 2.1.6: Canakinumab versus standard care/placebo: Serious adverse events
16
16
Analysis 1.2.1: Anakinra versus standard care/placebo: Time to clinical improvement
17
17
Analysis 1.2.2: Anakinra versus standard care/placebo: Time to WHO Clinical Progression Score of level 7 or above
18
18
Analysis 1.2.3: Anakinra versus standard care/placebo: Time to death
19
19
Analysis 2.2.1: Canakinumab versus standard care/placebo: Time to clinical improvement
20
20
Analysis 2.2.2: Canakinumab versus standard care/placebo: Time to WHO Clinical Progression Score of level 7 or above
21
21
Analysis 2.2.3: Canakinumab versus standard care/placebo: Time to death
22
22
Sensitivity analysis 1.3.1 (publication status): Anakinra versus standard care/placebo: All‐cause mortality D60 or above
23
23
Sensitivity analysis 1.4.1 (number analysed): Anakinra versus standard care/placebo: Clinical improvement D28
24
24
Sensitivity analysis 1.4.2 (number analysed): Anakinra versus standard care/placebo: Clinical improvement D60 or above
25
25
Sensitivity analysis 1.4.3 (number analysed): Anakinra versus standard care/placebo: WHO Clinical Progression Score of level 7 or above D28
26
26
Sensitivity analysis 1.4.4 (number analysed): Anakinra versus standard care/placebo: WHO Clinical Progression Score of level 7 or above D60 or above
27
27
Sensitivity analysis 1.4.5 (number analysed): Anakinra versus standard care/placebo: All‐cause mortality D28
28
28
Sensitivity analysis 1.4.6 (number analysed): Anakinra versus standard care/placebo: All‐cause mortality D60 or above
29
29
Sensitivity analysis 1.4.7 (number analysed): Anakinra versus standard care/placebo: Adverse events
30
30
Sensitivity analysis 1.4.8 (number analysed): Anakinra versus standard care/placebo: Serious adverse events
31
31
Sensitivity analysis 2.3.1 (number analysed): Canakinumab versus standard care/placebo: Clinical improvement D28
32
32
Sensitivity analysis 2.3.2 (number analysed): Canakinumab versus standard care/placebo: WHO Clinical Progression Score of level 7 or above D28
33
33
Sensitivity analysis 2.3.3 (number analysed): Canakinumab versus standard care/placebo: All‐cause mortality D28
34
34
Sensitivity analysis 2.3.4 (number analysed): Canakinumab versus standard care/placebo: All‐cause mortality D60 or above
35
35
Sensitivity analysis 2.3.5 (number analysed): Canakinumab versus standard care/placebo: Adverse events
36
36
Sensitivity analysis 2.3.6 (number analysed): Canakinumab versus standard care/placebo: Serious adverse events
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Caricchio CAN‐COVID 2021 {published and unpublished data}
    1. Caricchio R, Abbate A, Gordeev I, Meng J, Hsue PY, Neogi T, et al, CAN-COVID Investigators.Effect of canakinumab vs placebo on survival without invasive mechanical ventilation in patients hospitalized with severe COVID-19: a randomized clinical trial. JAMA 2021;326(3):230-9. [DOI: 10.1001/jama.2021.9508] - DOI - PMC - PubMed
Cremer Three C Study 2021 {published data only}
    1. Cremer PC, Sheng CC, Sahoo D, Dugar S, Prada RA, Wang KM et al, the Three C study group.Double-blind randomized proof-of-concept trial of canakinumab in patients with COVID-19 associated cardiac injury and heightened inflammation. European Heart Journal Open 2021;43(10):1055-63. [DOI: 10.1002/clc.23451] - DOI - PMC - PubMed
Declercq COV‐AID 2021 {published data only (unpublished sought but not used)}
    1. Declercq J, Van Damme KF, Leeuw ED, Maes B, Bosteels C, Tavernier SJ, et al.Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet. Respiratory Medicine 2021;9(12):1427-38. [DOI: 10.1016/S2213-2600(21)00377-5] - DOI - PMC - PubMed
Derde REMAP‐CAP 2021 {published data only (unpublished sought but not used)}
    1. Derde LP, The REMAP-CAP Investigators.Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19. The REMAP-CAP COVID-19 immune modulation therapy domain randomized clinical trial. medRxiv 2021. [DOI: 10.1101/2021.06.18.21259133] - DOI
Kyriazopoulou SAVE‐MORE 2021 {published and unpublished data}
    1. Kyriazopoulou E, Poulakou G, Milionis H, Metallidis S, Adamis G, Tsiakos K, et al.Early anakinra treatment for COVID-19 guided by urokinase plasminogen receptor. medRxiv [Preprint] 2021. [DOI: 10.1101/2021.05.16.21257283] - DOI
    1. Kyriazopoulou E, Poulakou G, Milionis H, Metallidis S, Adamis G, Tsiakos K, et al.Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nature Medicine 2021;27(10):1752-60. [DOI: 10.1038/s41591-021-01499-z] - DOI - PMC - PubMed
Mariette CORIMUNO‐19 Collaborative 2021 {published and unpublished data}
    1. Mariette X, the CORIMUNO-19 Collaborative group.Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. Lancet. Respiratory Medicine 2021;9(3):295-304. [DOI: 10.1016/S2213-2600(20)30556-7] - DOI - PMC - PubMed

Additional references

Attaway 2021
    1. Attaway AH, Scheraga RG, Bhimraj A, Biehl M, Hatipoğlu U.Severe covid-19 pneumonia: pathogenesis and clinical management. BMJ 2021;372:n436. - PubMed
Barkas 2021
    1. Barkas F, Ntekouan SF, Kosmidou M, Liberopoulos E, Liontos A, Milionis H.Anakinra in hospitalized non-intubated patients with coronavirus disease 2019: a systematic review and meta-analysis. Rheumatology 2021;60(12): 5527-37. - PMC - PubMed
Boutron 2020a
    1. Boutron I, Chaimani A, Meerpohl JJ, Hróbjartsson A, Devane D, Rada G, et al.The COVID-NMA project: building an evidence ecosystem for the COVID-19 pandemic. Annals of Internal Medicine 2020;173(12):1015-7. - PMC - PubMed
Boutron 2020b
    1. Boutron I, Chaimani A, Devane D, Meerpohl JJ, Rada G, Hróbjartsson A, et al.Interventions for the prevention and treatment of COVID-19: a living mapping of research and living network meta-analysis. Cochrane Database of Systematic Reviews 2020, Issue 11. Art. No: CD013769. [DOI: 10.1002/14651858.CD013769] - DOI
Boutron 2020c
    1. Boutron I, Chaimani A, Ghosn L.Interleukin (IL)-1 blocking agents for the treatment of COVID-19 A living systematic review. Zenodo 23 October 2020. [DOI: 10.5281/zenodo.5698219] - DOI
Boutron 2021
    1. Boutron I, Chaimani A, Ghosn L.Interleukin (IL)-1 blocking agents for the treatment of COVID-19 A living systematic review. Zenodo 8 November 2021. [DOI: 10.5281/zenodo.5698123] - DOI
Cabanac 2021
    1. Cabanac G, Oikonomidi T, Boutron I.Day-to-day discovery of preprint-publication links. Scientometrics 2021;126:5285–304. - PMC - PubMed
Cantini 2020
    1. Cantini F, Goletti D, Petrone L, Najafi Fard S, Niccoli L, Foti R.Immune therapy, or antiviral therapy, or both for COVID-19: a systematic review. Drugs 2020;80(18):1929-46. - PMC - PubMed
Cavalli 2021
    1. Cavalli G, Dagna L.The right place for IL-1 inhibition in COVID-19. Lancet. Respiratory Medicine 2021;9(3):223-4. - PMC - PubMed
Chaimani 2018
    1. Chaimani A, Mavridis D, Higgins JP, Salanti G, White IR.Allowing for informative missingness in aggregate data meta-analysis with continuous or binary outcomes: extensions to metamiss. Stata Journal 2018;18(3):716-40. - PMC - PubMed
Davidson 2021
    1. Davidson M, Menon S, Chaimani A, Evrenoglou T, Ghosn L, Graña C, et al.Dataset: Interleukin (IL)-1 blocking agents for the treatment of COVID-19 A living systematic review. Zenodo 15 January 2022. [DOI: 10.5281/zenodo.5853927] - DOI
Dinarello 2012
    1. Dinarello CA, Simon A, Meer JW.Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nature Reviews Drug Discovery 2012;11(8):633-52. - PMC - PubMed
GRADEpro GDT  [Computer program]
    1. McMaster University (developed by Evidence Prime) GRADEpro GDT.Hamilton (ON): McMaster University (developed by Evidence Prime), accessed 21 February 2021. Available at gradepro.org.
Higgins 2021
    1. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s).Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.
Horby 2021
    1. Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L et al.Dexamethasone in Hospitalized Patients with Covid-19. New England Journal of Medicine 25 February 2021;384(8):693-704.
Juul 2020a
    1. Juul S, Nielsen EE, Feinberg J, Siddiqui F, Jørgensen CK, Barot E, et al.Interventions for treatment of COVID-19: a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project). PLOS Medicine 2020;17(9):e1003293. Erratum in: PLoS Med. 2020 Dec 29;17(12):e1003517. - PMC - PubMed
Juul 2020b
    1. Juul S, Nielsen EE, Feinberg J, Siddiqui F, Jørgensen CK, Barot E et al.Interventions for treatment of COVID-19: second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project). medRxiv [Preprint] 2020.
Khan 2021
    1. Khan FA, Stewart I, Fabbri L, Moss S, Robinson K, Smyth AR, et al.Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19. Thorax 2021;76(9):907-19. - PubMed
Kim 2020
    1. Kim MS, An MH, Kim WJ, Hwang TH.Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: a systematic review and network meta-analysis. PLOS Medicine 2020;17(12):e1003501. - PMC - PubMed
Kirkham 2018
    1. Kirkham JJ, Altman DG, Chan AW, Gamble C, Dwan KM, Williamson PR.Outcome reporting bias in trials: a methodological approach for assessment and adjustment in systematic reviews. BMJ 2018;362:k3802. - PMC - PubMed
Kyriazopoulou 2021
    1. Kyriazopoulou E, Huet T, Cavalli G, Gori A, Kyprianou M, Pickkers P, et al, International Collaborative Group for Anakinra in COVID-19.Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis. Lancet Rheumatology 2021;3(10):e690-7. - PMC - PubMed
La Rosée 2019
    1. La Rosée P, Horne A, Hines M, Bahr Greenwood T, Machowicz R, Berliner N, et al.Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood 2019;133(23):2465-77. - PubMed
Mavridis 2015
    1. Mavridis D, White IR, Higgins JP, Cipriani A, Salanti G.Allowing for uncertainty due to missing continuous outcome data in pairwise and network meta-analysis. Statistics in Medicine 2015;34(5):721-41. - PMC - PubMed
Mavridis 2018
    1. Mavridis D, Chaimani A, EXhimiou O, Salanti G.Missing outcome data in meta-analysis. Evidence Based Mental Health 2018;21(3):123. - PMC - PubMed
Mullen 2020
    1. Mullen JL, Tsueng G, Abdel Latif A, Alkuzweny M, Cano M, Haag E et al.Outbreak.info. Available at: https://outbreak.info Accessed 24 January 2022.
Oikonomidi 2020
    1. Oikonomidi T, Boutron I, Pierre O, Cabanac G, Ravaud P, COVID-19 NMA Consortium.Changes in evidence for studies assessing interventions for COVID-19 reported in preprints: meta-research study. BMC Medicine 2020;18(1):402. - PMC - PubMed
Ouzzani 2016
    1. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A.Rayyan — a web and mobile app for systematic reviews. Systematic Reviews 2016;5(1):210. - PMC - PubMed
Pasin 2021
    1. Pasin L, Cavalli G, Navalesi P, Sella N, Landoni G, Yavorovskiy AG, et al.Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies. European Journal of Internal Medicine 2021;86:34-40. - PMC - PubMed
Peter 2021
    1. Peter AE, Sandeep BV, Rao BG, Kalpana VL.Calming the storm: natural immunosuppressants as adjuvants to target the cytokine storm in COVID-19. Frontiers in Pharmacology 2021;11:83777. - PMC - PubMed
Pierre 2021
    1. Pierre O, Riveros C, Charpy S, Boutron I.Secondary electronic sources demonstrated very good sensitivity for identifying studies evaluating interventions for COVID-19. Journal of Clinical Epidemiology 2021;141:46-53. - PMC - PubMed
Pile 2015
    1. Pile KD, Graham GG, Mahler SM.Interleukin 1 Inhibitors. In: Parnham M, editors(s). Encyclopedia of Inflammatory Diseases. Basel, Switzerland: Springer Basel, 2015:1-5.
Putman 2021
    1. Putman M, Chock YP, Tam H, Kim AH, Sattui SE, Berenbaum F, et al, COVID-19 Global Rheumatology Alliance.Antirheumatic disease therapies for the treatment of COVID-19: a systematic review and meta-analysis. Arthritis & Rheumatology 2021;73(1):36-47. - PMC - PubMed
REACT 2021
    1. The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group.Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. JAMA 2021;326 (6):499–518. [DOI: ] - PMC - PubMed
Riley 2011
    1. Riley RD, Higgins JP, Deeks JJ.Interpretation of random effects meta-analyses. BMJ 2011;342:d549. - PubMed
Schünemann 2019
    1. Schünemann HJ, Higgins JP, Vist GE, Glasziou P, Akl EA, Skoetz N, et al.Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.
Shakoory 2016
    1. Shakoory B, Carcillo JA, Chatham WW, Amdur RL, Zhao H, Dinarello CA, et al.Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial. Critical Care Medicine 2016;44(2):275-81. - PMC - PubMed
Siemieniuk 2020
    1. Siemieniuk RA, Bartoszko JJ, Ge L, Zeraatkar D, Izcovich A, Kum E, et al.Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ 2020;370:m2980. - PMC - PubMed
Sims 2010
    1. Sims JE, Smith DE.The IL-1 family: regulators of immunity. Nature Reviews Immunology 2010;10(2):89-102. - PubMed
Somagutta 2021
    1. Somagutta MK, Lourdes Pormento MK, Hamid P, Hamdan A, Khan MA, Desir R, et al.The safety and efficacy of anakinra, an interleukin-1 antagonist in severe cases of COVID-19: a systematic review and meta-analysis. Infection & Chemotherapy 2021;53(2):221-37. - PMC - PubMed
Sterne 2019
    1. Sterne JA, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al.RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366:l4898. - PubMed
Talaie 2020
    1. Talaie H, Hosseini SM, Nazari M, Fakhri Y, Mousavizadeh A, Vatanpour H, et al.Is there any potential management against COVID-19? A systematic review and meta-analysis. DARU Journal of Pharmaceutical Sciences 2020;28(2):765-77. - PMC - PubMed
Tierney 2007
    1. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR.Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8(16). [DOI: ] - PMC - PubMed
Turner 2012
    1. Turner RM, Davey J, Clarke MJ, Thompson SG, Higgins JP.Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews.. International Journal of Epidemiology 2012;41(3):818-27. - PMC - PubMed
van de Veerdonk 2020
    1. de Veerdonk FL, Netea MG.Blocking IL-1 to prevent respiratory failure in COVID-19. Critical Care 2020;24(1):445. - PMC - PubMed
White 2008
    1. White IR, Higgins JP, Wood AM.Allowing for uncertainty due to missing data in meta-analysis--part 1: two-stage methods. Statistics in Medicine 2008;27(5):711-27. - PubMed
WHO 2020a
    1. World Health Organization.Clinical management of severe acute respiratory infection when novel coronavirus (‎nCoV)‎ infection is suspected: interim guidance; 12 January 2020. Available at: apps.who.int/iris/handle/10665/332299.
WHO 2020b
    1. World Health Organization.Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). Available at https://www.who.int/publications/i/item/report-of-the-who-china-joint-mi....
WHO Working Group 2020
    1. WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection.A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases 2020;20(8):e192-7. - PMC - PubMed
Worldometer 2020
    1. COVID Live - Coronavirus Statistics - Worldometer. Available at worldometers.info/coronavirus/ Accessed 12 November 2021.

Associated data

LinkOut - more resources